At current levels, we believe AMGN scores above BMY, buoyed by solid fundamentals and recent positive estimate revisions.

Discover 9 promising small molecule drug discovery companies that recently raised funding for their potentially breakthrough ...

Just a few months after raising $200 million in third-round financing, immunology specialist Zenas ... acceleration in the number of biotech companies seeking public listings after a two-year ...

R&D spending across the global pharmaceutical sector climbed 1.5% in 2024, according to unreleased data from Evaluate Pharma.

Bio Usawa, a private biotech company focused on boosting drug access in Africa, inked a deal with cleanroom and laboratory ...

From my colleague Adam Feuerstein: French drug maker Sanofi is acquiring the small biotech Vigil Neuroscience for $470 ...

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) ...

Here's our list of the leaders in Massachusetts tech, biotech and climate tech who aren't just surviving, but moving their ...

Merck is expanding in oncology, immunology, and vaccines through acquisitions and R&D. Find out what makes MRK a stable GARP ...

Dr. Austin's appointment comes at a transformative period for VERAXA and I’m looking forward to working with him as we enter the next phase in VERAXA’s journey,” commented Christoph Antz, Ph.D., CEO ...

Story April 9 - Vincerx Pharma: With two attempts to merge with other companies having ... In a shift to focus on immunology and inflammation indications, the biotech is halting further ...

The antibody market has become a cornerstone of modern biotechnology and pharmaceutical industries, underpinning a vast array of diagnostic and therapeutic applications. Antibodies, which are proteins ...